Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates
Jean Philippe Stephan1, Katherine R Kozak, Wai Lee T Wong
1Protein Chemistry Department, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. stephanj@gene.com
Abstract:
With more than 34 targets being investigated and nearly 20 clinical trials at various phases of development, antibody-drug conjugates (ADCs) hold a lot of promise for improving oncological malignancy therapy. This therapeutic strategy designed to specifically or preferentially deliver a cytotoxic agent to tumor cells through conjugation to a monoclonal antibody is not new. Although this approach is relatively simple conceptually, the history of ADCs clearly attests to the high degree of complexity in their development. Each component of an ADC is important to achieve efficacy with minimal toxicity, and the ability to monitor this multicomponent therapeutic entity is deemed to be critical for their successful optimization. In this article we review the different bioanalytical strategies that have been implemented to characterize various ADCs and discuss the challenges and issues associated with these approaches.
Insights
Antibody-drug conjugates (ADCs) show promise in cancer therapy. This review covers bioanalytical strategies for characterizing these complex therapies and discusses development challenges.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Antibody-drug conjugates (ADCs) are an evolving class of targeted cancer therapeutics.
- ADCs leverage monoclonal antibodies to deliver cytotoxic agents specifically to tumor cells.
- Despite conceptual simplicity, ADC development is complex, requiring careful optimization of each component.
Purpose of the Study:
- To review current bioanalytical strategies for characterizing antibody-drug conjugates (ADCs).
- To discuss the challenges and issues associated with the development and monitoring of ADCs.
- To highlight the critical role of bioanalysis in optimizing ADC efficacy and minimizing toxicity.
Main Methods:
- Review of existing literature on bioanalytical techniques for ADC characterization.
- Discussion of various analytical platforms used to assess ADC components and overall drug product.
- Exploration of challenges in measuring drug-antibody ratio, payload, and free drug.
Main Results:
- Multiple bioanalytical strategies are employed for ADC characterization, including mass spectrometry and immunoassays.
- Challenges include assessing heterogeneity, ensuring payload stability, and quantifying low drug concentrations.
- The development of robust bioanalytical methods is crucial for successful ADC optimization and clinical translation.
Conclusions:
- Effective bioanalytical strategies are essential for the successful development and optimization of antibody-drug conjugates (ADCs).
- Addressing the complexities of ADC characterization requires a multi-faceted analytical approach.
- Continued innovation in bioanalysis will support the advancement of ADC-based cancer therapies.
